Clinical Trial Update: A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy of rucaparib in metastatic breast cancer with a BRCAness genomic signature has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Rucaparib (rucaparib)

Snippet

Sponsor: UNICANCER | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED